An Oxford University trial, a world first, is looking at whether inoculating volunteers with doses of different combinations of two currently approved COVID-19 vaccines is effective.
Celgene and Kyn Therapeutics enter a licensing agreement to develop Kyn’s immuno-oncology pipeline for investigative therapies after Celgene was acquired by BMS.